Alimentary lymphoma is one of the most commonly diagnosed neoplasms of the cat. The incidence of this disease has increased significantly over the past 15 years during the post-feline leukemia era. Despite the common prevalence of this disease, appropriate diagnosis and treatment can be challenging. There are two main forms of feline alimentary lymphoma: the small-cell (lymphocytic, well-differentiated, low-grade) lymphoma variety and the large-cell (lymphoblastic, high-grade) lymphoma variety. These two diseases are related; however, each presents its own diagnostic and therapeutic challenges. Additionally, it can be difficult to differentiate these malignancies from other nonneoplastic diseases such as inflammatory bowel disease and other chronic inflammatory conditions of the gastrointestinal tract. The purpose of this article is to tackle the challenges of this allusive disease with a step-by-step approach to diagnosis, staging, and therapy.
H ematopoietic tumors are by far the most common neoplasms of domestic cats. These tumors represent one third of all malignancies diagnosed in cats. Ninety percent of the hematopoietic tumors diagnosed in cats are lymphoma (LSA). 1, 2 There are many varied presentations of lymphoma in the cat including nasal LSA, cranial mediastinal LSA, multicentric LSA, renal LSA, central nervous system (CNS) LSA, and alimentary LSA. The prevalence of alimentary LSA has increased significantly in the last 15 years. This increase is a direct result of the commercialization and widespread use of the feline leukemia (FeLV) vaccine. FeLV virus is associated with the development of cranial mediastinal LSA, multicentric LSA, renal LSA, and CNS LSA 1, 2 . With the advent of the vaccine and better husbandry techniques to limit the exposure of susceptible cats to the virus, the veterinary field has seen a sharp decline in the number of newly diagnosed cases in most geographic areas of the country.
In this post-FeLV era, cats are living longer and developing alimentary LSA at a much higher frequency than was previously reported. Older articles have reported that alimentary LSA represented 32% of the newly diagnosed feline LSA cases. 2 More recent articles have demonstrated that up to 72% of the newly diagnosed feline LSA cases are alimentary in origin. 2 Although FeLV antigenemia is not commonly associated with alimentary LSA, it may play a role in the development and progression of this disease that has yet to be defined. Identification of FeLV with a standard serum enzyme-linked immunosorbent assay test (snap test) is positive in less than 40% (0%-38%) of cases. 1, 2 However, polymerase chain reaction (PCR) analysis has identified replication competent virus in the tissues of cats with alimentary LSA that were previously exposed to the virus, even if they were not viremic. 1, 2 Other reports suggest that feline immunodeficiency virus (FIV) may also play an occult role in the development of this disease. 2 Alimentary LSA in the cat typically involves the small intestine, stomach, mesenteric lymph nodes, and liver. Other organs that may be involved include the mouth, esophagus, and pancreas. [1] [2] [3] [4] [5] Large-cell LSA may extend beyond the alimentary system involving the spleen, peripheral lymph nodes, thoracic lymph nodes, and bone marrow. [1] [2] [3] [4] [5] Small-cell LSA is typically contained within the alimentary system. Lesions can be focal or diffuse. Affected cats may present with a small bowel obstruction secondary to a focal mass lesion. These cats may present acutely with no previous history of gastrointestinal symptoms. Other affected cats may have a more chronic presentation of weight loss, lethargy, inappetance, unkempt hair coat, vomiting, and diarrhea. It is important to note that vomiting is not a key symptom of this disease. 6, 7 Classifications of Feline LSA There are several classifications of alimentary LSA in the cat. Small-cell LSA (synonyms: well-differentiated LSA, lymphocytic LSA, low-grade LSA) is the most prevalent. It represents 75% of the alimentary LSA cases diagnosed in cats. 2 Male domestic shorthair cats seem to be predisposed to this dis-ease. There are conflicting articles regarding the most common immunophenotype associated with the various classifications. 2, 8, 9 More recent evidence has suggested that lowgrade alimentary LSA is more likely to be T-cell LSA, and high-grade alimentary LSA is more likely to be B-cell LSA. 2, 9 Large-cell LSA (synonyms: high-grade LSA, lymphoblastic LSA) also has an older male, domestic shorthair predisposition. These malignancies often spread beyond the alimentary tract. They are characterized by a rapid onset and progression resulting in acute and often severe clinical signs. Intermediate-grade alimentary LSA is not as well described as the previous classifications. These malignancies often require more aggressive therapy than small-cell LSA; however, they may not behave as aggressively as the large-cell variety. 2 Finally, large, granular cell LSA often starts in the alimentary system of the cat before rapidly spreading to other organ systems. This is an aggressive LSA that rarely has a meaningful response to therapy. Cats often present with acute clinical signs that rapidly progress. These cells contain cytoplasmic granules that can be demonstrated on Giemsa stains, which explains their name, and are thought to be of the T-cell/ natural killer cell immunophenotype. 1 
Risk Factors for Alimentary LSA in the Cat
Risk factors associated with alimentary LSA are not welldocumented. One study by Bertone and coworkers (2002) reported an association between environmental tobacco smoke exposure and the development of malignant LSA in cats. 10 Cats with any exposure had a 2.4-fold increased risk of developing LSA. Cats with more than 5 years of environmental tobacco smoke exposure had a 3.2-fold relative risk.
The most controversial potential risk factor for the development of alimentary LSA is a suspected association with chronic inflammation such as inflammatory bowel disease. Although it is easy to imagine these two diseases as a continuum, this may not be the case in cats. Various contrasting reports have only muddied the waters regarding this topic; however, a recent report may add credence to the theory for an association between LSA and inflammation. 6, 8, 11, 12 This article suggests that cats with vaccine-associated sarcomas (a tumor known to be directly related to inflammation) are at an increased risk for developing LSA. 12 Diet has also been suggested as a possible risk factor for alimentary LSA; however, there is no literature or evidence to support this theory. The theory stems from the relative and absolute increase in the overall numbers of cats diagnosed with alimentary LSA over the past 20 years. Concurrently, significant changes in the dietary composition of commercial cat foods have occurred; most notable are the changes made in response to feline urinary tract diseases. 1 Why Is Diagnosing Alimentary LSA so Difficult?
Other than LSA, there are many reasons for the infiltration of immune cells into the small intestine of the cat. Chronic infections with agents such as Mycobacteria, Helicobacter, Giardia, Histoplasma, Toxoplasma, and others can lead to a similar disease presentation to LSA. 13 Chronic food allergies and idiopathic causes such as lymphocytic-plasmacytic enteritis are other causes. T-cell infiltrative diseases such as enteric-associated T-cell infiltration (EATi) are particularly difficult to differentiate from lymphocytic LSA in the cat. 2, 8 In a pilot study analyzing more than 600 samples of feline LSA, several cases that were initially determined to be lymphocytic LSA by the first pathologist were reclassified as EATi. 8 Determining the clonality of these cells in the absence of mucosal congestion, edema, and fibrosis may be the best way to distinguish between the two disease processes. However, methods for determining clonality using flow cytometry or PCR have not been worked out well. There are no published studies referring to the sensitivity and specificity of such tests in association with feline alimentary LSA. For other lymphoid malignancies, the sensitivity of PCR for antigen receptor rearrangements is approximately 60% in the cat compared with Ͼ80% in the dog. Feline alimentary LSA represents a special challenge because of the tissue samples typically acquired. Samples from mesenteric lymph nodes are likely the best samples for PCR for antigen receptor rearrangements. Those lymph nodes that are closely associated with the affected intestine would likely have accumulated lymphocytes from all along the intestinal tract, including the areas of interest. Intestinal endoscopic biopsies may lead to false positives because it is possible to get a cluster of clonally related cells within the intestinal biopsy. Ideally, lymph node samples could be frozen, or impression smears could be used as well. The test could be attempted using endoscopic biopsies; however, it may be very difficult to interpret the results without further investigation and application of the methods involved (A. Avery, personal communication, 2008).
Small-cell Alimentary LSA
Small-cell LSA is one of the most common neoplastic disease processes diagnosed in the domestic cat today. These malignancies tend to have a slow onset and progression with a nebulous and chronic history of weight loss. 1, 6, 14, 15 For some cats, thickened intestinal loops or abdominal masses are found incidentally. On abdominal palpation, the intestines often feel "ropey" and thickened. Mesenteric lymph nodes may be mild to moderately enlarged and potentially palpable. Rarely, cats present with acute symptoms associated with intussusception, obstruction, or perforation with septic peritonitis. 1, 6, 15 Weight loss and lethargy may be the only presenting signs for many cats. Up to 10% of cats may be hypercalcemic as a paraneoplastic condition and present with polyuria and polydipsia. 2 Cats presenting with signs consistent with small-cell alimentary LSA are often geriatric. There are many diseases that these older cats can have that would cause similar signs or may be concurrent with LSA. A few of the differential diagnoses for these symptoms include inflammatory bowel disease (IBD), infectious causes of small bowel inflammation, intestinal or visceral mast cell disease, chronic pancreatitis, or chronic renal failure. It is important to do a thorough workup with a systematic approach to ensure nothing is overlooked. In addition to a thorough physical examination, basic blood work (complete blood count [CBC] and biochemistry panel) should be obtained on all cats. Based on the blood work and urinalysis, chronic or acute renal disease should be ruled out. Thyroid hormone levels (total T4 or free T4) can rule out hyperthyroidism. A positive test result for FeLV or FIV may raise suspicion for a neoplastic or infectious agent as the cause. Additional laboratory work can be performed at the Texas A&M University Gastrointestinal Laboratory (www.cvm.tamu.edu/gilab, phone 979-862-2861, fax 979-862-2864). Feline pancreatic lipase immunoreactivity (fPLI) tests can be performed to look for pancreatitis. This test has been shown to be more sensitive for detecting pancreatitis than either serum trypsin-like immunoreactivity (TLI) or abdominal ultrasound in feline patients. 16 In addition, serum cobalamin (B 12 ) and folate levels should be performed in cats with small intestinal disease. Many cats require supplementation of cobalamin before they will respond appropriately to therapy regardless of the diagnosis. The fPLI assay requires 500 L of serum and cobalamin, and folate levels require 400 L of serum. These tests can help to rule out pancreatitis in the cat and determine if supplementation of cobalamin is necessary.
In addition to laboratory tests, imaging is an essential diagnostic tool for staging alimentary LSA. Cats presenting with more acute signs of obstruction or septic peritonitis will often have abnormalities present on abdominal radiographs. Cats with a more chronic presentation may have normal abdominal radiographs. Additional imaging, such as an abdominal ultrasound, may increase suspicion for a neoplastic disease. More than 90% of cats with alimentary LSA of any kind will have ultrasonographic abnormalities 1, [3] [4] [5] . These abnormalities consist mostly of diffuse thickening of the small intestinal wall, stomach, and occasionally the colon with loss of layering, lymphadenopathy, and intestinal wall masses (more common with large-cell varieties). Additionally, the liver and spleen may appear diffusely infiltrated. [3] [4] [5] Chest radiographs can be used to identify possible lymphadenopathy in the thorax. This is very rare in cats with smallcell LSA because their disease is typically limited to the gastrointestinal system. FeLV-positive cats should have chest radiographs to rule out LSA in the cranial mediastinum. Chest radiographs may also identify any pneumonia that has resulted from aspiration secondary to chronic vomiting. Lastly, geriatric cats may have more than one problem and chest films may help to determine any anesthetic risks, such as hypertrophic cardiomyopathy, which are common in older felines.
Procurement of a diagnostic tissue sample is the last step in achieving a definitive diagnosis of LSA in the cat. Fine-needle aspirates are rarely helpful for small-cell LSA. The neoplastic lymphocytes are well-differentiated and appear normal. Without tissue architecture, it is often impossible to differentiate a normal lymphocyte from a small neoplastic lymphocyte. Therefore, a biopsy is typically required. Endoscopic biopsies are more accurate than initially thought. They are less invasive than an exploratory laparotomy and often require less anesthesia time. Approximately 70% of the time a diagnostic sample can be collected this way. 2 However, this requires the neoplastic tissue to be within the endoscopic retrieval zone (ie, the stomach, duodenum, or colon). Most cats have superficial neoplastic lesions in the mucosa that allow for endoscopic biopsy. 2 Occasionally, cats will have lesions located deeper in the intestinal wall. These can be missed because endoscopy does not provide a full-thickness sample. 1,2 Lastly, endoscopy is operator dependent. An experienced person is far more likely to acquire good diagnostic samples than a novice.
Surgical exploration of the abdomen allows for the highest yield; however, it is the most invasive approach for retrieving a diagnostic sample. With laparotomy, full-thickness biopsies can be procured. Lymph node biopsies and liver biopsies can also be achieved. Any obstructive masses can be removed with a resection and anastomosis of the affected intestine. Care must be taken to anastomose any surgical sites correctly. Intestinal anastomoses often dehisce more readily because of delayed or inefficient healing secondary to LSA infiltration. 1 Often the above steps are adequate for diagnosis of smallcell alimentary LSA. However, in rare cases the diagnosis remains elusive. These cases may require additional diagnostics. Immunohistochemical analysis of the tissue may be helpful. If all cells in the given tissue sample are of a single phenotype, this may support a diagnosis of LSA. 2, 8, 9, 17 However, certain disease processes can lead to an accumulation of a single phenotype, such as EATi. In addition, some LSA cases may have mixed B-cell and T-cell neoplastic populations. 2, 8 Flow cytometry may also help to identify a population of cells with specific lymphocyte markers. The demonstration of a clonal population of lymphocytes is the single best way to achieve a diagnosis of LSA. However, as discussed above, there is still much work to be done before this is a reliable way to differentiate small-cell LSA from other similar disease processes.
Once a diagnosis of small-cell alimentary LSA is made, therapy can be initiated. It is important to note that initiating immunosuppressive therapy (ie, prednisone) before a diagnosis of LSA is made can severely inhibit the clinician's ability to diagnose LSA. Staging for this disease has already been done with the previously described workup. No additional tests need to be done unless other laboratory work (ie, leukemic on CBC necessitating a bone marrow aspirate) suggests the need for it. The treatment of choice for small-cell alimentary LSA in the cat is chemotherapy. The drug of choice is chlorambucil with prednisone. 1 There are many differing administration protocols; however, one has not been proven to be superior to the others. The author uses a pulse-dosing protocol because it allows for administration by the owner of chemotherapy every 2 weeks as opposed to several times a week. A dose of 20 mg/m 2 by mouth once every 2 weeks is often adequate and only rarely produces side effects. Chlorambucil is available in 2-mg tablets. These tablets are
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coated and may be broken for 1-mg dose increments. When prescribing more than one tablet per dose, it is often easiest to place them in an empty clear capsule so they may be administered all at once. All clients and staff should wear gloves when handling or administering this medication whether it is in a capsule or not. If a tablet needs to be cut in half, this, ideally, should be done under a hood. If no hood is available, this can be done over an absorbent pad. The person handling the medication should be wearing a mask if pills are broken and the area should be cleaned with diluted bleach afterward. The adsorbent pad should be discarded as chemotherapy waste with the gloves and mask.
Monitoring while on chemotherapy can be done with regular CBCs. A CBC should be done before starting chemotherapy as part of staging. One week after the first dose, another CBC should be done and again before the second dose. This weekly blood work should be done for the first few doses of chemotherapy. Once it has been determined that this is a safe and effective dose for the patient, the CBCs can be performed every other week (before each dose) and then every other dose after a few months of therapy. Cats that are on chlorambucil long term may only need a CBC every 6 weeks.
Long-term use of any alkylating agent can lead to permanent damage to the bone marrow. A trend of dropping neutrophil or platelet values is important to note, even if they remain within the reference range. Values that drop and recover are acceptable; values that do not recover, however, necessitate an alteration in protocol. Chemotherapy should be discontinued for those animals that are consistently at or below 1500 segmented neutrophils/L and/or 75,000 platelets/L. A periodic drop in neutrophil counts or platelet counts below these reference levels followed by a recovery necessitate a delay in chemotherapy dosing, but not discontinuation of the drug.
Cyclophosphamide, single-agent doxorubicin, and COP (cyclophosphamide, vincristine [Oncovin] , and prednisone) protocols can be used as rescue agents for those cats that progress while on chlorambucil. 1, [18] [19] [20] The prognosis for cats with small-cell alimentary LSA is quite good. The median survival time for cats treated with chlorambucil is 18 to 24 months. 1 Those cats that have a good initial response (complete response) to therapy have a better prognosis than those only achieving moderate or no response. It may take up to 3 or 4 doses of chemotherapy to see the full effects of a response. 1, 2 Those not responding at that point should be switched to a different, more aggressive protocol. Immunophenotype has no prognostic value in the cat. 17 Large-cell Alimentary LSA Large-cell alimentary LSA often presents with more severe and acute symptoms than small-cell LSA. The vast majority of these cats (Ͼ80%) have palpable intraabdominal abnormalities (masses, thickened intestines, hepatosplenomegaly). 1, 7 They often are anorexic, have significant weight loss, and are more likely to present with acute signs associated with obstruction and septic abdomen due to perforation or intussusceptions. 1,2 Cats may or may not present with a history of vomiting or diarrhea.
The initial workup and diagnostic plan are the same for large-and small-cell alimentary LSA in the cat. The largest difference between the two diseases is that a diagnosis may be made with a fine-needle aspirate alone for large-cell LSA. Reactive lymph nodes can look very similar to those effaced by LSA; therefore, the results have to be interpreted careful- ly. 1 Biopsy may still be required in some cases. Additionally, large-cell LSA is often found outside of the gastrointestinal tract as well. Additional staging tests such as a bone marrow aspirate (BMA) are necessary for complete staging. 1 Although this test does not change the treatment protocol, infiltration of the bone marrow represents a more disseminated disease process and a worse prognosis. Some owners may decide to be less aggressive if the prognosis is worse.
In the cat, one of the easiest places to collect an adequate BMA sample is the proximal humerus. The cat should be heavily sedated or anesthetized and maintained on gas anesthesia for the duration of the procedure. A small (ϳ2 cm ϫ 2 cm) square area of fur is clipped over the proximal humerus (Fig 1) . The area is prepped with an antiseptic scrub such as betadine or chlorhexadine and alcohol. A scalpel blade is used to make a small incision in the skin just over the greater tubercle. This can be done before the last scrub of the area. A bone marrow needle (Jamshidi intraosseous bone marrow needle; Cardinal Health, Dublin, Ohio) is used (Fig 2) . An 18-gauge needle is an appropriate size for a cat. The needle is grasped like a pencil just above the edge of the most distal plastic rim. The base of the apparatus is placed against the palm of the hand. The needle is pushed through the skin, and the other hand is used to grab the elbow and externally rotate the limb. The needle point is placed against the bone at a 45°a ngle (to the humerus) downward (toward the elbow) (Fig 1) . The wrist should be held in a straight line with the elbow as pressure is applied. Twist the wrist back and forth while pushing into the bone. There may be a pop as the marrow cavity is entered. On average, three fourths of the needle should be buried into the bone. Once the needle is seeded, the cap and stylet are removed, and a 10-to 12-mL Luer lock syringe is quickly attached and screwed onto the bone marrow needle. A repeated rapid suction should be applied to the plunger until a small amount of marrow is seen in the hub of the syringe. A large amount of marrow is not necessary because hemodilution becomes a problem when larger amounts are collected. The needle should then be grasped at the base of the plastic and twisted to pull the entire apparatus, including the syringe, out of the bone. Small drops should be placed on slides and the slides should be spread out or smeared immediately. Bone marrow clots faster than blood, and the last few steps from the aspiration to the smear preparation should be performed very quickly. Any remaining marrow material may be placed in an ethylenediamine tetraacetic acid purple-top tube. Please see Figure 1 for an image of the necessary materials. A drape should be used, especially if the landmarks need to be palpated repeatedly. However, an experienced clinician may only need sterile gloves. It is important to stain a slide and examine it for bone marrow spicules while the cat is still sedated or anesthetized. This ensures a good sample was obtained. A second attempt should be made if the sample is less than desirable.
Once the diagnosis and staging are complete, therapy can be initiated. Large-cell LSA requires more aggressive chemotherapy than small-cell LSA. The CHOP protocol is often the gold standard of therapy. This protocol is a 25-week protocol consisting of cyclophosphamide, doxorubicin (hydroxydaunarubicin), vincristine (Oncovin; Gensia Sicor Pharmaceuticals, Inc., Irvine CA), and prednisone in an alternating schedule (Table 1) . This chemotherapy schedule is given weekly for the first 9 weeks (2 cycles), then every other week for the remaining 2 cycles. The common side effects of these individual drugs are listed in Table 2 . Other protocols commonly used include COP, single-agent doxorubicin, and CHOP with methotrexate (Animal Medication Center protocol). 1, 2, 18 Administration of cyclophosphamide is similar to that of chlorambucil because it can be given orally. This drug can be compounded to the appropriate dose. It is available in 25-mg and 50-mg tablets. These tablets cannot be broken. Vincristine is administered intravenously only. It is available in 1-mg/mL vials. It is often given with a butterfly catheter rather than a venous catheter because of the small volume administered. A catheter can be used to ensure extravasation does not occur. To decrease the stress to the patient and allow for adequate restraint, an Elizabethan collar may be placed on the patient to avoid the need to scruff or stretch the patient. Many of these cats are geriatric and may have concurrent orthopedic problems that make restraint uncomfortable for them (Fig 3, A) . Sedation should be used whenever necessary. The fur above the vein is clipped and the skin prepped with antiseptic and alcohol once or twice. The assistant manually occludes the vein, and the person administering the chemotherapy holds the foot firmly. A flushed butterfly catheter is placed into the vein. It is important to go straight into the vein and not through it. This can be achieved by lifting up slightly once the needle is in the vein. It is ideal to place the entire needle in the vein to minimize risk of extravasation (Fig  3, B) . One may not "back into" the vein. Only a forward motion is allowed. Backing into the vein is an indication that the needle has gone through it.
The butterfly catheter is then attached to a 3-way stop cock containing a syringe with 10 to 12 mL of sterile saline solution and a syringe with the chemotherapy in it (Fig 3, B) . The stop cock should be turned off to the chemotherapy. Two to 3 mL of sterile saline solution should be flushed into the vein after the assistant has stopped holding off the vein. This allows the integrity of the venipuncture to be assessed. If any fluid or blood leaks out of the vein, the needle should be removed, a pressure bandaged applied, and another vein attempted. The assistant should be able to feel a pulse of saline solution flush in the vein above the needle. Blood should be drawn back just enough to see a flash in the line of the butterfly catheter. An additional 2 mL of saline solution should be flushed in. This can be done several times with smaller amounts of flush. Once the clinician is convinced that the needle placement is adequate, the chemotherapy may be administered. The stop cock is turned off to the saline solution and the chemotherapy is flushed into the line. The stop cock is then immediately turned off to the chemotherapy again. Three to 5 mL of saline solution are flushed after the chemotherapy. Do not aspirate back once the chemotherapy has been administered. Once the line is flushed thoroughly, the needle is removed, a pressure bandage is applied, and the chemotherapy administration apparatus is disposed of as chemotherapy waste.
Infusions such as doxorubicin require intravenous catheter placement. Doxorubicin is a severe vesicant. Even a small amount of this drug extravasated is enough to potentially necessitate aggressive surgery or amputation. Therefore, extreme caution should be used when administering this drug. Many veterinarians choose to refer these patients to a specialist for this drug while they administer the others at their practice. Catheter placement must be perfect. The catheter must go straight into the vein and feed easily. One cannot back into the vein. A vein that has been punctured within 48 hours should not be used. Once the catheter has been placed and a t-port placed on the end, the same butterfly catheter and 3-way stop cock apparatus described above can be used. The catheter should be flushed and blood should be pulled back as described previously until the clinician is convinced of good catheter placement. Typically, 5 to 10 mL total of flush are needed initially. Cats will typically receive several milliliters of doxorubicin. These should be given slowly over 10 to 15 minutes. Do not aspirate back once the chemotherapy is being administered if at all possible. After the chemotherapy is administered, the catheter should be flushed with another 5 to 10 mL of saline solution before being removed and the pressure bandage is applied. All of the materials used should be disposed of as chemotherapy waste (Fig 3, C and D) .
All persons administering injectable chemotherapy should wear safety goggles or glasses, chemotherapy gloves, a mask, and a gown (Fig 3) . If a gown is not available, a buttoned-up laboratory coat will suffice. All facilities administering chemotherapy should have a well-stocked spill kit available (Fig 4) .
The prognosis for large-cell alimentary LSA is poor. The median survival time for cats treated with CHOP chemotherapy is 4 to 6 months. 1 Like small-cell alimentary LSA, a complete response to therapy is a positive prognostic indicator. Response rates to chemotherapy average around 60% to 70%; however, only 11% to 54% achieve a complete response. 1,2 Large-cell, granular LSA is very aggressive and also carries a poor prognosis. Often, cats will experience progressive disease in the face of aggressive therapy. Again, immunophenotype does not appear to carry any prognostic significance in the cat. 17 
Summary
As alimentary LSA has become more common in the feline population, the difficulties associated with diagnosing this disease have become more prevalent. A systematic approach will successfully provide a definitive diagnosis in most cases. However, there will always be difficult cases that require additional diagnostic techniques. Many researchers are currently working to create better diagnostic tests to make diagnosis of these difficult cases easier and more accessible. 
